Axtel Industries Limited Overview
Note on the NSE listing. Several platforms (Screener.in, Upstox, Sharpely, Anand Rathi) display an NSE symbol "AXTEL" and NSE prices. Others (Nirmal Bang, BFSL/Vogue) state the company is not traded on NSE. No dated NSE listing announcement was retrieved, so the BSE listing is the only one confirmed in this research.
Axtel Industries is a niche Indian original equipment manufacturer (OEM) of engineered process systems for the food-processing value chain. It designs, fabricates, automates and commissions both turnkey plants and standalone equipment, covering raw-material reception, bulk-solids handling, size reduction, sieving, mixing, steam sterilisation, chocolate moulding and final processing. Its customers are large FMCG, confectionery, spice, dairy, bakery, beverage, malted-drink and aqua-feed processors, plus a smaller base in pharmaceuticals and chemicals. The company runs a single 40,000 m² campus at Halol, near Vadodara, and has long-standing technical associations with Wenger (USA) for extrusion and AnuTec (Switzerland) for powder handling. It is a Gold-certified OEM partner of Rockwell Automation. Financially, Axtel is small (FY2026 revenue ₹223.8 crore), debt-free, cash-generative and a high dividend payer. Its fortunes are tied to the food industry's capex cycle and to the mix of complex orders in a given year. A 2026 exclusive licence for IISc cryogenic grinding technology signals a move into non-food ultra-fine powders.
Company's own description
The company's MD&A (as reproduced by IIFL) describes Axtel as engaged in manufacturing custom-designed food-processing plants and machinery to each client's requirements and specifications. It calls itself a leading supplier of process engineering equipment and turnkey systems to the food and pharmaceutical industries. The MD&A states that the company operates in only one segment: manufacturing food-processing equipment. It links the company's growth directly to growth in the food-processing industry. [Source: Axtel MD&A via IIFL; Screener.in "About", citing Annual Report 2024]
The corporate website says Axtel brings more than 33 years of experience in customised solutions for food processing. It cites expertise in turnkey systems, product development and customer service, and a corporate policy it calls the "4C approach": Comprehensive Process Knowledge, Continuous Product Innovation, Commitment to Quality and Customer-Centric Approach. [Source: axtelindia.com/our-company]
Business model
Axtel is a project-based, engineer-to-order (ETO) capital-goods business. The value chain runs as follows:
-
Process engineering and design. In-house designers conceptualise process flows, size equipment and develop 3D plant layouts using CAD.
-
Fabrication. Stainless-steel fabrication uses laser cutting, water-jet cutting, inverter TIG welding, CNC forming, grit blasting, painting and polishing. Heat treatment and precision machining are outsourced to strategic partners.
-
Electrical and automation. Panels are designed to IEC standards. PLC, HMI and SCADA software is developed in-house, and efficiency is monitored to ISA-88/95 standards.
-
Installation and commissioning, followed by after-sales service.
[Source: axtelindia.com]
According to CARE, raw materials are procured mainly when an order is received, which limits but does not remove exposure to commodity prices. Contracts are mostly fixed-price. [Source: CARE Ratings PR, 5 Feb 2026]
Revenue model mix
| Revenue type | Character | Disclosure status |
|---|---|---|
| Turnkey process systems (complete plants) | High-value, multi-month, milestone-billed projects | Revenue split not publicly disclosed |
| Individual process equipment | Standard or customised machines supplied singly | — |
| Spares, service and commissioning | Recurring aftermarket | — |
| Licensing / royalty | None at present; the IISc licence (Sept 2026) makes Axtel a royalty payer, not a recipient | Not applicable |
| Subscription | — | Not applicable |
Our independent characterisation is that revenue is overwhelmingly product and project revenue recognised as orders are executed and dispatched. Aftermarket revenue is probably a minority share, but its size is not disclosed.
Customer types and end-markets
CARE describes a base of more than 150 reputed customers, mainly large organised FMCG companies in India and abroad. The top-customer list changes each year with order flow, apart from a few marquee accounts. [CARE, Feb 2026]
End-markets disclosed by the company (via Capital Market/Business Standard and CARE):
-
confectionery and chocolate
-
malted drinks
-
aqua feed
-
ready-to-eat foods
-
bakery and biscuits
-
dairy products
-
beverages
-
instant mixes
-
snack foods
-
spices, condiments and seasonings
Secondary markets are pharmaceuticals, chemicals and cosmetics (grinding and milling). [StockAnalysis company profile; IIFL summary]
Independent characterisation
Axtel is best understood as a specialist bulk-solids and food-process engineering house. Its moat is application know-how (especially spice sterilisation, powder handling and chocolate lines), hygienic design (it is a registered EHEDG member), and in-house automation. It is not a high-volume machinery maker. The economics follow from that:
Lumpy revenue: FY2025 revenue fell 20% and FY2026 rose 25%.
Mix-driven margins: EBITDA margin swung between 12% and 20% in FY2022–FY2026.
Low capital intensity: Capex was ₹2–11 crore a year.
Strong customer advances: Payable and advance days are high, which helped the cash conversion cycle fall to 76 days in FY2026.
Strategy
Stated strategy themes
-
Customer-centric, engineer-to-order solutions, i.e. the 4C approach and "Right – the first time" delivery.
-
Full value-chain coverage, from raw-ingredient handling to final processing.
-
Continuous product innovation, including an R&D and test centre for size reduction, mixing, sieving and conveying.
Hygienic design and automation leadership: through EHEDG membership and Rockwell Gold OEM partnership.
- Import substitution / Atmanirbhar Bharat, explicitly invoked in the IISc licence announcement.
Strategic initiatives (last 24 months)
| Initiative | Date | Description | Target / KPI |
|---|---|---|---|
| ESOP 2024 | Introduced 2024 (implemented FY2025–26) | Employee stock options to attract and retain key talent | — |
| Capacity expansion (consolidation) | Opened Nov 2023; ramp-up FY2024–FY2026 | New sheds, material handling, solar panels, health centre | Supports CARE's ₹350 crore TOI upgrade trigger |
| Automation upgrade (Rockwell Automation) | Case study published c. 2024–25 | Fully automated chocolate moulding lines; spice-blending reporting covering 100+ ingredients | Precision, compliance, safety |
| R&D and test centre | Ongoing (website) | Trial facility for bulk-solids processes | Not quantified |
| IISc cryogenic grinding licence | 7 Sep 2026 | Exclusive commercialisation of a counter-rotating pin mill plus cryogenic conveying system; prototype transferred | Consideration up to ₹3 crore plus sales-linked royalties capped at ₹3 crore |
| Higher shareholder payouts | FY2025–FY2026 | Payout of 99% in FY2025 and 62% in FY2026 | No formal policy target retrieved |
| Solar energy | Nov 2023 | Rooftop solar at the expanded plant | Capacity not disclosed |
Cost programmes
None formally announced. Cost discipline appears mainly through procuring materials only when orders are received (CARE).
Medium-term targets and guidance
Management does not publish numerical guidance, investor presentations or earnings-call transcripts (none were retrieved). The only quantified external benchmarks are CARE's rating sensitivities:
Upside triggers: total operating income above ₹350 crore with PBILDT margin above 16%; tangible net worth above ₹200 crore; operating cycle below 90 days.
Downside triggers: total operating income below ₹200 crore on a sustained basis; gearing above 0.5x; operating cycle above 150 days.
Products & Services
Because Axtel has a single segment, the catalog is organised by the company's own two product families: Process Systems (turnkey lines) and Process Equipment (individual machines). Launch years, versions and prices are not publicly disclosed for any product. Pricing is project-specific and quoted, mostly on fixed-price contracts (CARE).
Process Systems (turnkey)
| Product line | What it does | Typical target customer | Notes |
|---|---|---|---|
| Solutions for Chocolates & Confectionery | Complete chocolate lines, from chocolate paste mixers to moulding lines and cooling tunnels; includes depositors, temperers and thermoregulation units | Chocolate and confectionery majors | Moulding lines fully automated with Rockwell Automation controls (Rockwell case study) |
| Ingredients Management Systems | Automated reception, storage, dosing and weighing of major, minor and micro ingredients; the Rockwell case study cites management of 100+ ingredients in spice processing | FMCG, bakery, malted drinks, instant mixes, seasoning | Integrated PLC/SCADA batch control to ISA-88 |
| Size Reduction Systems | Complete grinding and milling plants for foodstuffs, pharma, cosmetics and chemicals | Spice, sugar, pharma, chemical processors | A cryogenic option is being added via the IISc licence (2026) |
| Sieving Systems | Plant-level sieving and grading lines for powders and granules | Flour, sugar, milk powder, pharma | Core offering |
| Mixing Systems | Batch and continuous blending systems, including cryogenic mixers | Instant mixes, seasoning, nutrition | Core offering |
| Spices Processing Systems | Cleaning, grinding, pasteurisation and steam sterilisation of whole and ground spices | Spice brands and exporters | A flagship niche; serves export food-safety requirements |
| Steam Sterilization Systems | Microbial load reduction for spices, herbs and seeds using steam | Spice exporters, seasoning makers | Flagship niche offering |
| Customized Processing Solutions | Bespoke lines, e.g. food and feed extrusion (with Wenger technology), conveyor dryers and dehydration systems, frying systems, dewatering | Aqua feed, pet food, snacks, RTE | Extrusion is linked to the Wenger association |
[Source: axtelindia.com menu; IIFL summary; Tradomate; Rockwell case study]
Process Equipment (individual machines)
| Equipment family | Named products |
|---|---|
| Solids handling | Sack tip stations, bulk loaders, belt conveyors, cyclones, reverse jet filters, screw feeders with valve, metering screw feeders, magnets, dual tunnel diverter valves, blowers, idler roller conveyors, Z-bucket elevators, dump booths, octabin and tote tilters |
| Storage and discharge | Bag handling systems, storage tanks, intermediate bulk containers (IBCs), rotary vane valves, table feeders, bin activators, pneumatic knife gate and butterfly valves, cone discharge units, bagging stations, liquid injection pressure tanks, storage bins |
| Size reduction | Hammer mills, universal mills, nibblers, lump breakers, cone mills, knife mills, shredders, roller mills |
| Sieving and straining / cleaning and grading | Rotary sifters, gyratory sifters, inline rotary and gyratory sifters, graders, screeners, destoners, zig-zag classifiers, chocolate vibro-sieves, vacuum gravity separators |
| Mixing and blending | Mixers, process tanks, dough kneaders, cryogenic mixers (model names not disclosed) |
| Specialised process equipment | Steam sterilisers, moulding-line cooling tunnels, curved and dryer conveyors, chocolate depositors, temperers, thermoregulation units, extruders, khoa-making machines, dewatering screw presses, vacuum cabinet dryers, band dryers, scraped-surface heat exchangers, IBC/big-bag filling machines, horizontal wiped-film evaporators, shell-and-tube heat exchangers, steaming tunnels |
[Source: StockAnalysis company description, compiled from company materials; axtelindia.com]
Services
Engineering services: process-flow design, equipment sizing and 3D plant layouts.
Electrical and automation: IEC-compliant panel design and manufacture in a dust-proof assembly area, and PLC/HMI/SCADA programming.
Installation, commissioning and after-sales: - Product development and trials: an R&D and test centre for size reduction, mixing, sieving and pneumatic/mechanical conveying is described as "in the process of being established".
Flagship and emerging offerings
Flagship: spice steam sterilisation, chocolate moulding lines, ingredient-management automation, and powder-handling systems (with AnuTec know-how).
Emerging (2026): a high-performance grinding system with a counter-rotating pin mill and cryogenic conveying, licensed exclusively from FSID-IISc. It targets ultra-fine powders of polymers, rubbers, resins and natural materials, which are currently import-dependent. [BSE Reg. 30, 7 Sep 2026]
Financial Narrative
Basis: standalone, Ind AS, ₹ crore. Primary aggregation is Screener.in (BSE filings); revenue and gross profit are from StockAnalysis. FY2022–FY2026 = years ended 31 March 2022–2026.
Income statement
Notes:
-
Gross profit is aggregator-derived (StockAnalysis: total revenue less cost of revenue) and is not a company-reported line.
-
EBIT is derived as EBITDA less depreciation.
-
Diluted EPS equals basic EPS in reported figures; ESOP 2024 dilution was immaterial or not reported.
-
Net profit for FY2022–FY2023 is derived from EPS × 1.615 crore shares. FY2024–FY2026 are company-reported (₹32.13 crore, ₹18.03 crore, ₹31.16 crore).
-
DPS is per fiscal year of declaration:
-
FY2022: final ₹2.
-
FY2023: final ₹3.
-
FY2024: interim ₹6.
-
FY2025: interim ₹5 plus final ₹6.
-
FY2026: interim ₹12. The Board on 7 May 2026 recommended treating it as the final dividend, and the 62% payout on EPS of ₹19.29 is consistent with ₹12 in total.
-
Revenue CAGR FY2022–FY2026 (derived): (223.8/144.0)^(1/4) − 1 = 11.7%. Screener.in's trailing 5-year sales CAGR is 8% and 10-year is 13%. Its 5-year profit CAGR is 4%; 3-year is 15%.
Commentary. Revenue follows the food industry's capex cycle and order execution, not a steady growth path.
FY2022: revenue fell 5.7%, and EBITDA margin compressed to 12% as steel inflation hit fixed-price contracts.
FY2023–FY2024: two years of about 24–25% growth took revenue to a record ₹223 crore. EBITDA margin expanded to about 20% thanks to operating leverage and a richer mix of complex orders.
FY2025: a step back. CARE attributes the 20% revenue decline and the 615 bps PBILDT margin contraction (to 13.92%) to slower end-user capex, operating deleverage and lower execution of high-margin complex orders.
FY2026: a sharp V-shaped recovery to ₹223.8 crore (+25.3%) with PAT up 72.8%. The improvement was back-ended: Q2–Q4 delivered 87% of annual revenue.
Gross margin: reached a 5-year high of about 58% in FY2026 (aggregator basis). This suggests better pricing or mix, but "other operating expenses" (which likely include subcontracting) also rose sharply, so EBITDA margin (18%) did not fully match the gross-margin gain.
Quarterly trajectory (last 13 quarters)
[Source: Screener.in quarterly results, from BSE filings]
Quarterly commentary.
Q1 is seasonally weak: Q1 FY2026 revenue was ₹27.2 crore (−39% YoY) and Q1 FY2027 was ₹32.3 crore (+18.7% YoY). Q1 FY2027 PAT rose only 3.2% to ₹1.96 crore, and OPM of 7.8% was the second-lowest in 13 quarters. The stock fell about 8% on the day of the results (6 Aug 2026).
Q4 FY2025 tax: The effective tax rate was −6% (a tax credit), which flattered that quarter's PAT.
TTM to June 2026 (derived): revenue ₹228.9 crore, PAT ₹31.2 crore, EPS ₹19.32.
Balance sheet
Notes:
-
Total assets are company-reported at ₹215.64 crore for FY2026 (FilingReader).
-
Goodwill and intangibles are not separately disclosed and appear immaterial.
-
Working capital is not disclosed as a line item. Screener's "working capital days" fell from 105 (FY2022) to −7 (FY2026).
-
Book value per share for FY2022–FY2025 is derived (net worth / 1.615 crore shares).
-
CARE reports tangible net worth of ₹134 crore at 30 September 2025, and free liquidity of ₹99 crore at the same date.
-
Screener rounds borrowings to zero for FY2022–FY2026; CARE confirms "no outstanding debt" at 31 March 2025 and 30 September 2025.
Commentary. The balance sheet is pristine.
No debt: Debt was retired after FY2020, when borrowings were ₹8 crore.
Growing treasury: Investments, most likely liquid and mutual-fund holdings, rose from ₹18 crore to ₹81 crore over five years. CARE's ₹99 crore free-liquidity figure (Sept 2025) equals roughly 15% of today's market capitalisation.
Net worth growth was slow in FY2026: It rose only ₹2 crore because dividends paid (about ₹29 crore, derived) nearly matched PAT of ₹31.2 crore. Management is effectively distributing most of its earnings.
Fixed assets doubled: from ₹13 crore (FY2023) to ₹25 crore (FY2024) with the November 2023 expansion.
Cash flow
Notes:
-
Capex is derived as CFO minus FCF.
-
Dividends paid are derived from the per-share cash dividends paid within each fiscal year × 1.615 crore shares:
-
FY2022: FY2021 final ₹3.
-
FY2023: FY2022 final ₹2.
-
FY2024: FY2023 final ₹3 plus FY2024 interim ₹6.
-
FY2025: FY2025 interim ₹5.
-
FY2026: FY2025 final ₹6 plus FY2026 interim ₹12.
-
-
CARE reports CFO of ₹38 crore for FY2024 and ₹31 crore for FY2025, consistent with Screener.
Commentary.
FY2022: was the only negative-CFO year (−₹11 crore). Receivables rose to 116 days and inventory to 175 days as large orders sat mid-execution.
FY2026: was exceptional: CFO of ₹71 crore was about 2x EBITDA, driven by higher customer advances and payables (payable days rose from 101 to 125) and lower inventory days (155 to 128). Some of this release may reverse if order intake slows.
- Cumulative FY2022–FY2026 FCF of about ₹127 crore funded about ₹60 crore of dividends and an increase of about ₹63 crore in investments.
Key ratios
Notes:
-
ROE, ROA and asset turnover are derived from Screener P&L and balance sheet data.
-
ROCE is Screener-reported. ROIC is not disclosed; ROCE is the closest proxy, and with no debt and cash excluded, ROIC would be higher.
-
The current ratio and TOL/TNW are from CARE. CARE reports the current ratio as "2.38x as on 31 March 2024 (PY: 1.91x)", so 1.91 is FY2023.
-
Interest coverage for FY2024–FY2025 is from CARE. FY2026 is derived (quarterly EBITDA ₹40.7 crore / interest ₹0.25 crore).
-
Net debt/EBITDA for FY2024–FY2025 is derived from CARE free liquidity and Screener EBITDA.
-
Working-capital days and CCC are from Screener. CARE's "operating cycle" is 121 days for FY2024 and 127 days for FY2025, slightly different because of a different method.
Commentary. Returns are high for an Indian capital-goods company of this size: 5-year average ROE is about 20% and peak ROCE was 41% in FY2024. They are, however, volatile. The most important structural improvement is the cash conversion cycle, which fell from 147 days (FY2024) to 76 days (FY2026). CARE's positive rating trigger is an operating cycle below 90 days; Screener's CCC measure is now below that threshold, though CARE's own methodology may differ.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment revenue from operations (INR Cr) | 223.3 | 178.6 | 223.8 |
Segment YoY revenue growth (%) | 24.0 | -20.0 | 25.3 |
Segment operating profit / EBITDA (INR Cr) | 44.1 | 23.8 | 40.7 |
Segment EBITDA margin (%) | 19.7 | 13.3 | 18.2 |
Segment pre-tax profit (INR Cr) | 42.9 | 23.9 | 41.4 |
Contribution to total revenue (%) | 100 | 100 | 100 |
Income Statement and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Revenue from operations (INR Cr) | 144.0 | 180.1 | 223.3 | 178.6 | 223.8 |
Revenue growth YoY (%) | -5.7 | 25.1 | 24.0 | -20.0 | 25.3 |
Gross profit (INR Cr) | 68.7 | 84.8 | 116.0 | 90.5 | 129.1 |
Gross margin (%) | 47.7 | 47.1 | 51.9 | 50.7 | 57.7 |
Operating profit / EBITDA (INR Cr) | 17 | 23 | 44 | 24 | 41 |
EBITDA margin (%) | 12 | 13 | 20 | 13 | 18 |
Other income (INR Cr) | 5 | 4 | 3 | 5 | 6 |
Interest expense (INR Cr) | 0 | 1 | 2 | 1 | 0 |
Depreciation (INR Cr) | 3 | 2 | 3 | 4 | 5 |
Operating income EBIT (INR Cr) | 14 | 21 | 41 | 20 | 36 |
Operating (EBIT) margin (%) | 9.7 | 11.7 | 18.4 | 11.2 | 16.1 |
Profit before tax (INR Cr) | 19 | 23 | 43 | 24 | 41 |
Effective tax rate (%) | 26 | 25 | 25 | 25 | 25 |
Net profit (INR Cr) | 13.8 | 17.3 | 32.1 | 18.0 | 31.2 |
Net margin (%) | 9.6 | 9.6 | 14.4 | 10.1 | 13.9 |
EPS basic (INR) | 8.56 | 10.71 | 19.89 | 11.16 | 19.29 |
EPS diluted (INR) | 8.56 | 10.71 | 19.89 | 11.16 | 19.29 |
Dividend per share (INR) | 2 | 3 | 6 | 11 | 12 |
Dividend payout (%) | 23 | 28 | 30 | 99 | 62 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%) (Quarterly)
| Metric | Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sales (INR Cr) | 47.91 | 69.47 | 53.79 | 52.16 | 44.70 | 55.84 | 40.41 | 37.61 | 27.22 | 67.34 | 58.63 | 70.57 | 32.31 |
Operating profit (INR Cr) | 7.04 | 16.61 | 12.68 | 7.72 | 5.48 | 8.88 | 4.96 | 4.52 | 1.52 | 13.18 | 10.82 | 15.17 | 2.53 |
OPM (%) | 14.69 | 23.91 | 23.57 | 14.80 | 12.26 | 15.90 | 12.27 | 12.02 | 5.58 | 19.57 | 18.45 | 21.50 | 7.83 |
PBT (INR Cr) | 7.01 | 16.75 | 12.17 | 6.94 | 5.34 | 9.15 | 4.96 | 4.49 | 2.17 | 13.62 | 10.82 | 14.80 | 2.55 |
Net profit (INR Cr) | 5.32 | 11.92 | 9.58 | 5.31 | 4.11 | 5.90 | 3.26 | 4.76 | 1.90 | 10.12 | 7.98 | 11.16 | 1.96 |
EPS (INR) | 3.29 | 7.38 | 5.93 | 3.29 | 2.54 | 3.65 | 2.02 | 2.95 | 1.18 | 6.26 | 4.94 | 6.91 | 1.21 |
Balance Sheet and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Total assets (INR Cr) | 131 | 179 | 196 | 189 | 216 |
Net fixed assets (INR Cr) | 14 | 13 | 25 | 28 | 31 |
Capital work in progress (INR Cr) | 0 | 5 | 0 | 1 | 0 |
Investments (INR Cr) | 18 | 34 | 35 | 57 | 81 |
Other assets incl. inventory, receivables, cash (INR Cr) | 98 | 127 | 135 | 103 | 103 |
Free liquidity per CARE (INR Cr) | — | — | 60 | 79 | — |
Total debt (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Short-term debt (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Long-term debt (INR Cr) | 0 | 0 | 0 | 0 | 0 |
Net debt (INR Cr) | — | — | -60 | -79 | — |
Equity share capital (INR Cr) | 16 | 16 | 16 | 16 | 16 |
Reserves (INR Cr) | 65 | 80 | 97 | 106 | 108 |
Total equity / net worth (INR Cr) | 81 | 96 | 113 | 122 | 124 |
Other liabilities incl. customer advances and payables (INR Cr) | 50 | 83 | 83 | 66 | 91 |
Book value per share (INR) | 50.2 | 59.4 | 70.0 | 75.5 | 77.2 |
Cash Flow and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Cash from operating activities (INR Cr) | -11 | 30 | 39 | 31 | 71 |
Capital expenditure (INR Cr) | 2 | 5 | 11 | 7 | 8 |
Free cash flow (INR Cr) | -13 | 25 | 28 | 24 | 63 |
Cash from investing activities (INR Cr) | 14 | -20 | -9 | -25 | -28 |
Cash from financing activities (INR Cr) | -5 | -5 | -16 | -9 | -29 |
Dividends paid, derived (INR Cr) | 4.8 | 3.2 | 14.5 | 8.1 | 29.1 |
Share buybacks (INR Cr) | 0 | 0 | 0 | 0 | 0 |
CFO to EBITDA (%) | -36 | 157 | 33 | 156 | 197 |
Net cash flow (INR Cr) | -2 | 5 | 13 | -3 | 14 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
ROE on average equity (%) | 18.2 | 19.5 | 30.7 | 15.3 | 25.3 |
ROA on average assets (%) | 11.7 | 11.2 | 17.1 | 9.4 | 15.4 |
ROCE (%) | 22 | 26 | 41 | 20 | 30 |
Current ratio (x) | — | 1.91 | 2.38 | — | — |
Debt to equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net debt to EBITDA (x) | — | — | -1.36 | -3.29 | — |
Interest coverage, PBILDT/interest (x) | — | — | 27.86 | 36.80 | 163 |
Asset turnover (x) | 1.21 | 1.16 | 1.19 | 0.93 | 1.11 |
Debtor days | 116 | 125 | 81 | 67 | 74 |
Inventory days | 175 | 172 | 177 | 155 | 128 |
Payable days | 148 | 153 | 111 | 101 | 125 |
Cash conversion cycle (days) | 143 | 143 | 147 | 121 | 76 |
Total outside liabilities to tangible net worth (x) | — | — | 0.85 | 0.58 | — |
Revenue by Region
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Total revenue (INR Cr) | 223.3 | 178.6 | 223.8 |
Capital Markets
| Metric | 1 year | 3 years | 5 years | 10 years |
|---|---|---|---|---|
Stock price CAGR (%) | -10 | -8 | 5 | 20 |
Share Price History
| Date | Price | Source |
|---|---|---|
19 Sep 2024 | 460 | 5paisa |
8 Nov 2024 | 555.65 (market cap ₹898 crore) | Value Research |
11 Jul 2025 | 470 (52-week range then ₹370.5–680) | Kotak |
Nov 2025 | 490 | Upstox |
2 Apr 2026 | 389 | ICICIdirect |
12 Jun 2026 | 447.95 | Torus |
6 Aug 2026 | 465.50 intraday, before closing down about 8% to about ₹432 after results | Value Research; Univest |
28 Aug 2026 | 400.45 | Anand Rathi |
23 Sep 2026 | 450.35 | StockAnalysis |
16 Oct 2026 | 419 | Screener.in |
Price series (INR) | Nov 2024 | Jul 2025 |
Axtel share price (INR) | 555.65 | 470 |
Valuation Multiples
| Multiple | Axtel | Basis |
|---|---|---|
Market capitalisation (INR Cr) | 677 | Screener |
P/E (TTM) (x) | 21.7 | Screener; TTM EPS ₹19.32 |
P/B (x) | 5.4 | Derived: ₹419 / BVPS ₹77.2 |
EV (INR Cr) | about 596 | Derived: market cap minus FY2026 investments of ₹81 crore; operating cash not deducted, so EV is overstated |
EV/EBITDA TTM (x) | about 14 | Derived: ₹596 crore / TTM EBITDA of about ₹41.7 crore |
EV/Sales TTM (x) | about 2.6 | Derived: ₹596 crore / ₹228.9 crore |
Dividend yield (%) | 2.87 | Screener |
Per-Share Data and Returns & Leverage Ratios (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|
Dividend per share (INR) | 3 | 2 | 3 | 6 | 11 | 12 |
Dividend payout ratio (%) | 46 | 23 | 28 | 30 | 99 | 62 |
Credit Ratings
| Agency | Facility | Amount (INR Cr) | Rating | Outlook | Date |
|---|---|---|---|---|---|
CARE Ratings | Fund-based LT/ST: cash credit / packing credit | 12.00 | CARE A- / CARE A2+ | Stable | 5 Feb 2026 (reaffirmed) |
CARE Ratings | Non-fund-based ST: bank guarantee / letter of credit | 37.65 | CARE A2+ | — | 5 Feb 2026 |
CARE Ratings | Non-fund-based short term | 0.35 | CARE A2+ | — | 5 Feb 2026 |
Moody's / S&P / Fitch | — | — | Not rated | — | — |
Analyst Conclusions
Management guidance
None published. The only forward indicators are:
- CARE's citation of an order book of about ₹250 crore at 30 Sep 2025, and its expectation of a "gradual recovery in capex activity of key end-user industries".
Consensus growth expectations
None available; the stock has no sell-side coverage.
Bull case
-
Cycle upturn plus operating leverage. FY2026 showed that revenue near ₹224 crore delivers about 18% EBITDA margin and about 25% ROE. With an order book of about ₹250 crore and an FMCG capex recovery (Q2–Q4 FY2026 YoY growth of 21–88%), FY2027–28 revenue could reach new highs above the FY2024 peak, with margins near 20%.
-
Valuation underpinned by cash and yield. About ₹81–99 crore of liquidity (12–15% of market capitalisation), a 2.9% dividend yield and EV/EBITDA of about 14x look undemanding for a debt-free company earning 30% ROCE. Value Research shows Axtel's P/E at a deep discount to peers.
-
New growth vector. Exclusive IISc cryogenic grinding technology opens non-food markets (polymers, rubbers, resins) with import-substitution tailwinds. The maximum outlay of about ₹6 crore is small relative to ₹31 crore of annual PAT.
Bear case
-
Structural low growth. The 5-year sales CAGR is only 8% and the profit CAGR 4% (Screener). The company has stayed below about ₹225 crore of revenue for three years, which suggests a ceiling on market reach without new geographies or capacity.
-
Margin and earnings fragility. Q1 FY2027 OPM of 7.8% and only 3% PAT growth despite 19% sales growth; a 615 bps margin swing in FY2025. Fixed-price contracts and limited pricing power with large buyers (CARE) mean profits can collapse in a downcycle.
-
Cash flow flattered by working capital, and illiquid governance. FY2026 CFO of ₹71 crore relied on payables stretching to 125 days. Institutional ownership is below 2%, there is no investor communication, and decisions sit with two long-tenured promoters, all of which limit re-rating potential.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Nov 2026 | Q2 FY2027 results; compare with Q2 FY2026 (sales ₹67.34 crore, PAT ₹10.12 crore) and look for a return of OPM above 18% |
| Jan–Feb 2027 | Q3 FY2027 results; annual CARE rating review (watch for movement toward the ₹350 crore TOI and sub-90-day operating-cycle triggers) |
| 1 Mar 2027 | Start of Ajay Desai's new five-year term |
| Mar 2027 | Size of the interim dividend (signal of FY2027 earnings confidence) |
| May 2027 | FY2027 audited results; any disclosure of order book or export share |
| Ongoing | First commercial orders for the cryogenic grinding system; commissioning of the R&D and test centre |
| Ongoing | Further accumulation by Solidarity Advisors or other institutions; any NSE listing clarification |
| Ongoing | Stainless-steel prices; FMCG capex announcements in India |
Analyst verdict
Axtel Industries is a well-run, conservatively financed niche engineering company whose investment case depends almost entirely on the food-processing capex cycle and on how efficiently it converts orders into margin. The evidence over five years is clear. The company earns high returns: ROCE ranged from 20% to 41% between FY2022 and FY2026, with no leverage. It turns those returns into real cash, with about ₹127 crore of free cash flow over five years, and it returns most of that cash to shareholders, paying out 99% in FY2025 and 62% in FY2026. CARE's rating upgrade to A- in 2025 and its reaffirmation in 2026 independently confirm the strength of the balance sheet.
Growth, however, has been unremarkable and highly volatile. Revenue has hit a ceiling of about ₹224 crore twice in three years, and a 20% drop in FY2025 showed how quickly profits fall when complex, high-margin orders slow down. The weak start to FY2027 (Q1 OPM of 7.8%) is consistent with the company's usual seasonality. Even so, it reminds investors that a single strong year does not make a trend.
At about ₹419 per share (21.7x trailing earnings, about 14x EV/EBITDA, 2.9% dividend yield, with roughly 12–15% of market capitalisation in liquid assets), the market is valuing Axtel as a quality cyclical rather than a compounder. That looks fair to modestly undervalued if FY2027 broadly holds FY2026's earnings. The upside case depends on three things: sustained revenue above ₹250 crore backed by the reported order book of about ₹250 crore, commercial traction for the IISc cryogenic grinding technology, and better disclosure that could broaden an institutional base currently below 2%.
Our verdict is constructive but cyclical. The key monitorables are H2 FY2027 margin recovery, order-intake commentary in the next CARE review, and early evidence that the company can move beyond its long-standing revenue ceiling.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / key dates | Background |
|---|---|---|---|
Ajay Naishad Desai | Executive Director and Whole-time Director (promoter) | ED since at least 2011; signs results declarations; current term runs to 28 Feb 2027; re-appointment for five years from 1 Mar 2027 approved by the Board (6 Aug 2026) and shareholders (AGM 31 Jul 2026) | Public spokesman on automation (Rockwell case study) and on the IISc licence. |
Ajay Nalin Parikh (DIN 00453711) | Executive Director and Whole-time Director (promoter) | With Axtel since 1992; re-appointed 1 Aug 2013, 1 Aug 2018 and 1 Aug 2023 (five-year term); continuation to 31 Jul 2028 approved at AGM 2026 | First-class Bachelor of Engineering. Earlier career linked to the National Dairy Development Board ecosystem per AR 2013. Credited with developing a large range of equipment and setting up manufacturing. |
Rajendra K. Bhavsar | Chief Financial Officer | Tenure not disclosed | — |
Dharaben Mehulkumar Thakar | Company Secretary and Compliance Officer | From 2 Jun 2025 | Replaced CS Prerna Sudeep Bokil (resigned effective 31 May 2025) |
Board of Directors
| Director | Category | Notes |
|---|---|---|
Sandeep Lalwani | Chairman, Independent Director | On the board since at least 2012 |
Ajay Naishad Desai | Executive / Whole-time Director (promoter) | See above |
Ajay Nalin Parikh | Executive / Whole-time Director (promoter) | See above |
Ameet Nalin Parikh | Non-Executive Director (promoter group; related to Ajay Parikh) | Director since at least 2012 |
Ajit (Ajitsingh Mohansingh) Bubber (DIN 00454111) | Non-Executive Director | Retired by rotation and re-appointed at the AGMs of 10 Jul 2023 and 19 Aug 2025 |
Deepti Sharma | Independent Director | — |
Nimish Patel | Independent Director | — |
Paresh Jaisinh Rajda | Independent Non-Executive Director (per Blinkx) | Current status not confirmed in primary filings |
Board & Management Changes
| Date | Change |
|---|---|
13 May 2025 | CS Prerna Bokil resigns (effective 31 May 2025); CS Dharaben Thakar appointed (effective 2 Jun 2025) |
19 Aug 2025 | Ajit Singh Bubber re-appointed on rotation |
31 Jul 2026 | AGM approves Ajay Desai's re-appointment and Ajay Parikh's continuation as WTDs, plus revised remuneration from 1 Aug 2026 |
6 Aug 2026 | Board disclosure: Desai re-appointed from 1 Mar 2027; Parikh to continue until 31 Jul 2028 |
Shareholding Trend
| Holder category | Sep 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
Promoters (%) | 49.95 | 49.95 | 49.95 | 49.95 | 49.95 |
FIIs (%) | 0.00 | 0.02 | 0.62 | 0.41 | 0.41 |
DIIs (%) | 0.00 | 0.25 | 0.99 | 1.42 | 1.48 |
Public (%) | 50.06 | 49.79 | 48.45 | 48.23 | 48.17 |
Number of shareholders | 17,698 | 19,749 | 19,493 | 18,625 | 18,789 |
Major Shareholders
| Holder | Stake | Note |
|---|---|---|
Promoter group (Parikh, Desai and associated families) | 49.95% combined | — |
Solidarity Advisors Pvt. Ltd. and PACs | 5.20% | Rose from 4.76% (768,951 shares) via open-market purchase on 19 Jun 2026 |
Aanchal N. Mehta | Not disclosed (below 5% after sale) | — |
Domestic institutions (mutual funds etc.) | 1.48% | — |
Foreign portfolio investors | 0.41% | — |
Competitive Landscape
Key Competitors
| Competitor | Home country | Overlap with Axtel | Relative scale | Positioning vs Axtel |
|---|---|---|---|---|
Bühler AG | Switzerland | Grinding/milling, spice processing, chocolate and confectionery, extrusion | Multi-billion-dollar global leader | Technology and brand leader; much higher price point |
GEA Group | Germany | Food process systems, dairy, powder handling, extrusion | Multi-billion-euro | Broad portfolio; competes on large greenfield projects |
Hosokawa Micron Group | Japan | Size reduction, classification, powder processing | Large global | Fine/ultra-fine grinding leader; relevant to the cryogenic adjacency |
Royal Duyvis Wiener | Netherlands | Cocoa and chocolate processing | Mid-size global | Chocolate-line competitor |
Aasted / Sollich | Denmark / Germany | Chocolate moulding, enrobing, tempering, cooling tunnels | Mid-size global | Premium chocolate-equipment specialists |
Napasol AG | Switzerland | Spice and herb steam sterilisation | Niche | Direct competitor in spice sterilisation |
Russell Finex | UK | Sieves, separators, filters | Mid-size | Competes in sieving equipment |
Clextral | France | Twin-screw extrusion | Mid-size | Extrusion competitor (Axtel works with Wenger) |
Kilburn Engineering Ltd | India (listed) | Industrial dryers, food and chemical drying systems | — | Overlaps in dryers and dehydration |
HLE Glascoat Ltd | India (listed) | Process equipment, filtration and drying for pharma and chemicals | — | Overlaps in pharma and chemical equipment |
Mazda Ltd | India (listed) | Vacuum systems, evaporators, process equipment | — | Overlaps in evaporators and heat exchangers |
Unorganised and regional Indian fabricators (Gujarat, Maharashtra) | India | Standard conveyors, mixers, sifters | Fragmented | Compete on price for standalone equipment |
Competitor Detail
| Metric | Axtel FY2026 |
|---|---|
Revenue (INR Cr) | 223.8 |
Revenue growth (%) | 25.3 |
EBITDA margin (%) | 18 |
Net margin (%) | 13.9 |
Recent Developments
The company does not announce individual orders.



